ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 6 (2) 265-269    DOI: 10.1677/erc.0.0060265
Copyright © 1999 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ingle, J.
Right arrow Articles by Dowsett, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingle, J.
Right arrow Articles by Dowsett, M
Endocrine Related Cancer, Vol 6, Issue 2, 265-269
Copyright © 1999 by Society for Endocrinology

Articles

Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer

JN Ingle, VJ Suman, VC Jordan, and M Dowsett


Numerous comparative clinical trials have been conducted evaluating combination hormonal therapy involving the aromatase inhibitor aminoglutethimide, but there is no evidence for any superiority of this approach over single-agent therapy alone. The advent of new aromatase inhibitors with greater potency, selectivity, and better tolerability has prompted a reconsideration of the combined therapy approach, with attention being focused on pharmacologic and endocrinologic clinical research. The value of combining newer aromatase inhibitors with other hormonal agents remains to be established.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. N. Ingle
Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 480S - 485S.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Shozu, H. Sumitani, T. Segawa, H.-J. Yang, K. Murakami, T. Kasai, and M. Inoue
Overexpression of Aromatase P450 in Leiomyoma Tissue Is Driven Primarily through Promoter I.4 of the Aromatase P450 Gene (CYP19)
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2540 - 2548.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Endocrinology.